Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 861 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuromuscular Control Clear all
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 23, 2026, 2:28 PM EDT
Recruiting Phase 3 Interventional

Injection of Botulinum Toxin for Thumb Carpometacarpal Arthritis

NCT05990881
View directory record Official record
Conditions
Carpometacarpal Sprain, Thumb Sprain, Clostridium; Botulinum
Interventions
Botulinum toxin, Standard-of-care corticosteroid injections
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Not applicable Interventional

Collar Use for Cervical Radicular Pain

NCT04163939
View directory record Official record
Conditions
Cervical Radiculopathy
Interventions
Vista Therapy Collar, Placebo
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 23, 2026, 2:28 PM EDT
Not listed Phase 2 Interventional

Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

NCT04163419
View directory record Official record
Conditions
Schwannomatosis, Pain
Interventions
Tanezumab, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 23, 2026, 2:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Post-Concussion Musculoskeletal Injury Risks

NCT05122728
View directory record Official record
Conditions
Musculoskeletal Injury
Interventions
Post-Concussion Neuromuscular Function and Musculoskeletal Injury Risk Assessment
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 40 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
3
States / cities
Athens, Georgia • Bethesda, Maryland • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Ricolinostat in Patients With Painful Diabetic Peripheral Neuropathy

NCT03176472
View directory record Official record
Conditions
Painful Diabetic Peripheral Neuropathy
Interventions
ricolinostat, Placebo
Drug
Lead sponsor
Regenacy Pharmaceuticals LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
35
States / cities
Anniston, Alabama • Phoenix, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10

NCT03294707
View directory record Official record
Conditions
Amyloid Cardiomyopathy, Transthyretin-Related
Interventions
AG10 oral tablet, Placebo Oral Tablet
Drug
Lead sponsor
Eidos Therapeutics, a BridgeBio company
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows

NCT00752297
View directory record Official record
Conditions
Glabellar Rhytides
Interventions
Preservative-free Saline, Mentor Purified Toxin
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 23, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

NCT05581199
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm

NCT04671082
View directory record Official record
Conditions
Back Muscle Spasm, Back Pain, Back Strain, Back Spasm Upper, Muscle Spasm, Acute Pain
Interventions
Tolperisone Hydrochloride, Placebo
Drug
Lead sponsor
Neurana Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
56
States / cities
Surprise, Arizona • Little Rock, Arkansas • Canoga Park, California + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients

NCT01396239
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
AVI-4658 (Eteplirsen), Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
7 Years to 13 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy

NCT00113620
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
Neurodex
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
44
States / cities
Mesa, Arizona • Sun City, Arizona • Hot Springs, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cost Information on Carpal Tunnel Syndrome Treatment Decisions

NCT03880812
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Societal cost
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 89 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
6
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

NCT00053417
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Placebo, 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2011 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03703882
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne
Interventions
Edasalonexent, Placebo
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

NCT03401073
View directory record Official record
Conditions
Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions
Intravenous immunoglobulin, 0.9% Sodium Chloride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 23, 2026, 2:28 PM EDT
Not listed Phase 3 Interventional

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients

NCT04762758
View directory record Official record
Conditions
Charcot-Marie-Tooth Disease
Interventions
(RS)-baclofen, naltrexone hydrochloride and D-sorbitol, Placebo
Drug
Lead sponsor
Pharnext S.C.A.
Other
Eligibility
16 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Los Angeles, California • Sacramento, California • New Britain, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 23, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

NCT02466243
View directory record Official record
Conditions
Dermatomyositis
Interventions
JBT-101, Placebo
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional

A Study to Determine if Levetiracetam Will Assist Those Suffering From Chronic Idiopathic Axonal Polyneuropathy.

NCT00156689
View directory record Official record
Conditions
Chronic Idiopathic Axonal Polyneuropathy
Interventions
levetiracetam
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2008 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effect of 'Cramp Bites' on Period Cramps in Women Aged 18-25

NCT06227676
View directory record Official record
Conditions
Dysmenorrhea Primary, Dysmenorrhea, Menstrual Discomfort, Menstrual Problem, Menstrual Cycle Abnormal, Menstrual Pain, Period Pain, Period Problem, PMS, Premenstrual Syndrome, PCOS, PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, PCOS (Polycystic Ovary Syndrome) of Left Ovary, PCOS (Polycystic Ovary Syndrome) of Right Ovary, Polycystic Ovary Syndrome, Premenstrual Dysphoric Disorder, Cramps, Ovarian Cysts
Interventions
Cramp Bites by Aunt Flo's Kitchen
Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

NCT02908685
View directory record Official record
Conditions
Muscular Atrophy, Spinal
Interventions
Placebo, Risdiplam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 25 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Palo Alto, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 23, 2026, 2:28 PM EDT
Completed Phase 2Phase 3 Interventional

NGX-4010 for the Treatment of Postherpetic Neuralgia

NCT00061776
View directory record Official record
Conditions
Herpes Zoster, Neuralgia, Pain, Peripheral Nervous System Diseases, Shingles
Interventions
Capsaicin Dermal Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
28
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2008 · Synced Oct 23, 2026, 2:28 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Treatment of Carpal Tunnel Syndrome With Dynamic Splinting

NCT00558116
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Dynamic splinting
Device
Lead sponsor
Advanced Centers for Orthopaedic Surgery and Sports Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Owings Mills, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2008 · Synced Oct 23, 2026, 2:28 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

NCT07596901
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Aritinercept, Placebo
Drug · Other
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
11
States / cities
Pasadena, California • Altamonte Springs, Florida • Boca Raton, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 23, 2026, 2:28 PM EDT